Description

Simple

A medication used to relieve inflammation and itching caused by various medical conditions in the skin.

Clinical

A corticosteroid used for the management and symptomatic relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Overview

Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc. Research suggests that clobetasol propionate demonstrates superior pharmacologic efficacy in the treatment of psoriasis when compared to halcinonide.

Pharmacology

Indication

Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Pharmacodynamic

Information currently not available.

Mechanism of action

The precise mechanism of action of topical corticosteroids is unclear. However they possess anti-inflammatory, antipruritic, and vasoconstrictive actions.

New research indicates that halcinonide activates MBP (myelin basic protein) expression via smoothened receptor activation. This finding sugge... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Systemic absorption of topical corticosteroids has produced reversible hypothalamicpituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent s... Read more

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Halcinonide
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
2,4-thiazolidinedione
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with 2,4-thiazolidinedione.
Acarbose
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Acarbose.
Acetohexamide
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Acetohexamide.
Acetyldigitoxin
The risk or severity of adverse effects can be increased when Halcinonide is combined with Acetyldigitoxin.
Acetyldigoxin
The risk or severity of adverse effects can be increased when Halcinonide is combined with Acetyldigoxin.
Adenovirus type 7 vaccine live
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Halcinonide.
AICA ribonucleotide
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with AICA ribonucleotide.
Albiglutide
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Albiglutide.
Alclometasone
The risk or severity of hypertension can be increased when Alclometasone is combined with Halcinonide.
Aldosterone
The risk or severity of hypertension can be increased when Aldosterone is combined with Halcinonide.
Allicin
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Allicin.
Alogliptin
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Alogliptin.
Amcinonide
The risk or severity of hypertension can be increased when Amcinonide is combined with Halcinonide.
AMG-222
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with AMG-222.
Aminoglutethimide
The therapeutic efficacy of Halcinonide can be decreased when used in combination with Aminoglutethimide.
Anagliptin
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Anagliptin.
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Halcinonide.
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Halcinonide.
Bacillus calmette-guerin substrain connaught live antigen
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Halcinonide.
Bacillus calmette-guerin substrain danish 1331 live antigen
The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Halcinonide.
3 References
  1. 1 . Draelos ZD: Demonstration of the biphasic release of 0.1% halcinonide cream. J Drugs Dermatol. 2015 Jan;14(1):89-90.PubMed: 25607913
  2. 2 . Ellis CN, Van Scott EJ: Clobetasol propionate cream versus halcinonide cream in psoriasis. Int J Dermatol. 1986 Jun;25(5):332-3.PubMed: 3522448
  3. 3 . Porcu G, Serone E, De Nardis V, Di Giandomenico D, Lucisano G, Scardapane M, Poma A, Ragnini-Wilson A: Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and RxRgamma Receptor Activation. PLoS One. 2015 Dec 10;10(12):e0144550. doi: 10.1371/journal.pone.0144550. eCollection 2015.PubMed: 26658258